Precision BioSciences Announces Appointment Of Gene Liau, Ph.D. And Bruce Mccreedy, Ph.D. To Management Team

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, the genome editing company, today announced two key additions to the executive team - Gene Liau, Ph.D., as Senior Vice President, Gene Therapy and Bruce McCreedy, Ph.D., as Senior Vice President, Cell Therapy.

"We are excited to welcome Gene and Bruce to the Precision team," said Matthew Kane, Chief Executive Officer of Precision BioSciences. "Their proven leadership and breadth of experience will undoubtedly prove critical to our gene and cell therapy product development programs.

Suggested Articles

The appointments are part of Verona’s efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease.

Syntimmune has had a roller-coaster few years, losing CEOs, gaining new ones and then being snapped up by Alexion in 2018 for up to $1.2 billion.

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.